 Tumor Necrosis Factor Receptor Superfamily, Member 7
"Tumor Necrosis Factor Receptor Superfamily, Member 7" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily found on most T-LYMPHOCYTES. Activation of the receptor by CD70 ANTIGEN results in the increased proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D018127
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.048 D23.050.301.264.894.127 D23.101.100.894.127
|
| Concept/Terms |
Tumor Necrosis Factor Receptor Superfamily, Member 7- Tumor Necrosis Factor Receptor Superfamily, Member 7
- CD27 Antigens
- TNFRSF7 Receptor
- Receptor, TNFRSF7
- T-Cell Activation Antigen
- Activation Antigen, T-Cell
- Antigen, T-Cell Activation
- T Cell Activation Antigen
- Antigen, CD27
- CD27 Antigen
- Antigens, CD27
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor Receptor Superfamily, Member 7".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- Tumor Necrosis Factor Receptor Superfamily, Member 7 [D12.776.543.750.705.852.760.048]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Tumor Necrosis Factor Receptor Superfamily, Member 7 [D23.050.301.264.894.127]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Tumor Necrosis Factor Receptor Superfamily, Member 7 [D23.101.100.894.127]
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor Receptor Superfamily, Member 7".
This graph shows the total number of publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 7" by people in this website by year, and whether "Tumor Necrosis Factor Receptor Superfamily, Member 7" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 4 | 0 | 4 | | 1999 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 2 | 0 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 2 | 0 | 2 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 7" by people in Profiles.
-
Ruschil C, Gabernet G, Lepennetier G, Heumos S, Kaminski M, Hracsko Z, Irmler M, Beckers J, Ziemann U, Nahnsen S, Owens GP, Bennett JL, Hemmer B, Kowarik MC. Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses. Front Immunol. 2020; 11:606338.
-
Kowarik MC, Astling D, Lepennetier G, Ritchie A, Hemmer B, Owens GP, Bennett JL. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics. 2021 01; 18(1):364-377.
-
Gherardin NA, Loh L, Admojo L, Davenport AJ, Richardson K, Rogers A, Darcy PK, Jenkins MR, Prince HM, Harrison SJ, Quach H, Fairlie DP, Kedzierska K, McCluskey J, Uldrich AP, Neeson PJ, Ritchie DS, Godfrey DI. Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Sci Rep. 2018 03 07; 8(1):4159.
-
Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Jun 20; 35(18):2028-2036.
-
Burchill MA, Tamburini BA, Kedl RM. T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs. Eur J Immunol. 2015 Nov; 45(11):3140-9.
-
Shin HM, Kapoor V, Guan T, Kaech SM, Welsh RM, Berg LJ. Epigenetic modifications induced by Blimp-1 Regulate CD8? T cell memory progression during acute virus infection. Immunity. 2013 Oct 17; 39(4):661-75.
-
Liubchenko GA, Appleberry HC, Striebich CC, Franklin KE, Derber LA, Holers VM, Lyubchenko T. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun. 2013 Feb; 40:111-21.
-
Sanchez PJ, Kedl RM. An alternative signal 3: CD8? T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling. Vaccine. 2012 Feb 01; 30(6):1154-61.
-
Asito AS, Piriou E, Jura WG, Ouma C, Odada PS, Ogola S, Fiore N, Rochford R. Suppression of circulating IgD+CD27+ memory B cells in infants living in a malaria-endemic region of Kenya. Malar J. 2011 Dec 13; 10:362.
-
Born WK, O'Brien RL. ?d T cells develop, respond and survive - with a little help from CD27. Eur J Immunol. 2011 Jan; 41(1):26-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|